As Enhertu’s reach continues to spread into additional forms of breast cancer, Daiichi Sankyo and AstraZeneca are ramping up ...

Enhertu is forecast to retain its dominant market position in the ADC landscape and reach global sales of $11.2bn by 2030.

ADCs, particularly Enhertu and datopotamab deruxtecan, are showing promising results. See why I rate the stock a buy.

Enhertu also improved the time to deterioration for pain and other factors in patients with HR-positive, HER2-low and ...

The results of the open-label DESTINY-Breast12 trial – reported at the ESMO cancer congress in Barcelona this weekend – ...

Patients with HER2-positive advanced or metastatic breast cancer received trastuzumab deruxtecan every 3 weeks.

Enhertu has shown 'unprecedented' trial results, giving hope to mums like Maggie Ngatai.

WILMINGTON, Del.--(BUSINESS WIRE)--Results from the DESTINY-Breast12 Phase IIIb/IV trial showed that ENHERTU ® (fam-trastuzumab deruxtecan-nxki) demonstrated substantial overall and intracranial ...

Daiichi Sankyo and AstraZeneca are padding the case for their antibody-drug conjugate Enhertu with new data demonstrating the ...

Congress 2024, recent results from the single-arm open-label DESTINYBreast-012 trial evaluating Daiichi Sankyo’s Enhertu ...

Daiichi Sankyo and AstraZeneca’s ENHERTU achieved a 61.6% progression-free survival rate at one year in patients with active or stable brain metastases in DESTINY-Breast12 Largest prospective ...